Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAT1 | P21673 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2470417 | 0.81 | LPAR3 (0.39) | CYP2C19LMNAFDPSTDP1 | |
| SCHEMBL2472181 | 0.81 | ALDH1A1 (0.37) | CA2CYP2C19LMNAFDPSGRM4 | |
| Phosphoric Acid SCHEMBL17477136 | 0.79 | TSHR (0.39) | CYP2C19LMNAFDPSGRM4TP53 | |
| SCHEMBL2782188 | 0.79 | TP53 (0.36) | CYP2C19LMNAFDPSGRM4TP53 | |
| Phosphoric Acid SCHEMBL17477137 | 0.79 | LPAR3 (0.38) | CYP2C19LMNAFDPS | |
| Ammonia Solution, Strong SCHEMBL27519730 | 0.79 | LPAR3 (0.38) | CYP2C19LMNAFDPS | |
| SCHEMBL9264971 | 0.79 | CYP2C19 (0.35) | CYP2C19LMNAFDPSGRM4TP53 | |
| SCHEMBL518185 | 0.78 | DGAT1 (0.41) | SAT1CA2GRM4PPARD | |
| SCHEMBL9961561 | 0.78 | CYP2C19 (0.38) | CYP2C19TP53TDP1 | |
| SCHEMBL10509715 | 0.78 | CYP2C19 (0.38) | CYP2C19TP53TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228503-A1 | TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-07-11 | — | — | US | disclosed |
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | CYANA THERAPEUTICS LLC | 2023-06-22 | — | — | US | disclosed |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEURODERM, LTD. (IL) | 2023-05-25 | — | — | US | disclosed |
| US-20230137764-A1 | PRODRUGS OF FULVESTRANT | ACQUIOM AGENCY SERVICES, AS COLLATERAL AGENT | 2023-05-04 | — | — | US | disclosed |
| US-10004740-B2 | Prodrugs of HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170173015-A1 | PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170174600-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | TANSNA THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| EP-0285975-A2 | Thermoplastic moulding compounds based on polyphenylene ether | BASF Aktiengesellschaft (DE) | 1988-10-12 | — | — | EP | disclosed |
| EP-0285976-A2 | Polyphenylene ether-based thermoplastic moulding compounds | BASF Aktiengesellschaft (DE) | 1988-10-12 | — | — | EP | disclosed |
| EP-0285967-A2 | Thermoplastic moulding compounds on the basis of polyphenylene ether | BASF Aktiengesellschaft (DE) | 1988-10-12 | — | — | EP | disclosed |
| EP-0285971-A2 | Thermoplastic moulding compositions based on styrene acrylonitrile copolymers and polyphenylene oxide | BASF Aktiengesellschaft (DE) | 1988-10-12 | — | — | EP | disclosed |
| US-4618633-A | Halogen-free self-extinguishing thermoplastic molding material | BASF AKTIENGESELLSCHAFT (DE) | 1986-10-21 | — | — | US | disclosed |
| EP-0192214-A2 | Self-extinguishing thermoplastic composition not containing halogen | BASF Aktiengesellschaft (DE) | 1986-08-27 | — | — | EP | disclosed |
| EP-0192154-A2 | Self-extinguishing thermoplastic composition not containing halogen | BASF Aktiengesellschaft (DE) | 1986-08-27 | — | — | EP | disclosed |
| EP-0176774-A2 | Halogen-free self-extinguishing thermoplastic moulding composition | BASF Aktiengesellschaft (DE) | 1986-04-09 | — | — | EP | disclosed |
| EP-0176775-A2 | Halogen-free self-extinguishing thermoplastic moulding composition | BASF Aktiengesellschaft (DE) | 1986-04-09 | — | — | EP | disclosed |
| EP-0173974-A2 | Process for preparing cyclic esters of phosphonic acids | BASF Aktiengesellschaft (DE) | 1986-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228503-A1 | TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORS | SSB, CGAS, STING1 | SAT1 1472/4885CA2 2571/4885CYP2C19 1205/4885 |
| US-20230137764-A1 | PRODRUGS OF FULVESTRANT | CYP19A1, PGR, ESR1 | SAT1 4774/4885CA2 3502/4885CYP2C19 25/4885 |
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | SAT1 2470/4885CA2 2463/4885CYP2C19 3640/4885 |
| US-20170174600-A1 | 2,5-DIALKYL-4-H/HALO/ETHER-PHENOL COMPOUNDS | COMT, DDT, TYR | SAT1 1925/4885CA2 1392/4885CYP2C19 213/4885 |
| US-20170173015-A1 | PRODRUGS OF HIV REVERSE TRANSCRIPTASE INHIBITORS | TYMP, RNGTT, REV1 | SAT1 540/4885CA2 4498/4885CYP2C19 112/4885 |
| US-10004740-B2 | Prodrugs of HIV reverse transcriptase inhibitors | TYMP, RNGTT, REV1 | SAT1 540/4885CA2 4498/4885CYP2C19 112/4885 |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | ENPP1, STING1, ENPP3 | SAT1 2826/4885CA2 1234/4885CYP2C19 3814/4885 |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | SAT1 2470/4885CA2 2463/4885CYP2C19 3640/4885 |
| US-20230277570-A1 | ENPP1 Inhibitors and Their Use for the Treatment of Cancer | ENPP1, ENPP3, ENTPD1 | SAT1 2470/4885CA2 2463/4885CYP2C19 3640/4885 |
| US-20230157985-A1 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | DDC, DDT, COMT | SAT1 456/4885CA2 919/4885CYP2C19 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.